Development of private healthcare in China – can private operators succeed and will competition drive quality? | Duke Kunshan University
Development of private healthcare in China – can private operators succeed and will competition drive quality?
Ms. A. Clancey Houston

CEO, Chinaco Healthcare Corporation China

Apr 19th 2016 12:00 to 13:00
Room 1079, Academic Building

Summary of Talk:

A discussion of the development of private hospitals in China, the difficulties of implementing high quality care in a constrained reimbursement environment, the key drivers for growth of healthcare services in China which might shape the market over the next 5 years.    


Brief Biography:    

For twenty years Ms. Houston has grown and led multi-national and integrated teams in building, promoting and protecting brands and businesses, particularly in the pharma and consumer health sectors, in the highly complex and issues-rich emerging markets of Asia Pacific. As CEO, Ms. Houston leads CHC’s China team in advancing CHC’s mission to improve the quality of healthcare services provided to the mainstream population in China through the acquisition and management of large general or mid-sized specialty hospitals.

She guides the ongoing development of CHC’s Shanghai-based Shared Services platform, which provides centralized finance, recruiting, procurement, compliance and legal support to CHC hospitals; and oversees the company’s network expansion through the acquisition and integration of private and public hospitals into the CHC network. Ms. Houston also serves as Chairman of the Board at CHC’s first facility, CHC International Hospital (CHCIH), a 1,000-bed general hospital (currently built out to 500 beds in Phase 1) located in Cixi City, Zhejiang Province; and at CHC’s second hospital, Zhenjiang Ruikang Hospital in Jiangsu Province. CHCIH is China’s first large-scale Sino-US joint venture general hospital.

Prior to joining CHC, Ms. Houston was Managing Director for Inventive Health Communications / China, part of inVentiv Health, a top-tier professional services organization that accelerates the clinical and commercial success of biopharmaceutical companies through CRO and commercialization services. She also spent a decade at global communications giant WPP where she specialized in crisis counsel and strategic integrated communications. Ms. Houston’s China-focused career began with consultancy Pacific Rim Resources, where she was tasked with conducting market research, competitor analysis, regulatory and joint venture partner advisory services for Fortune 500 corporates looking to enter the China market.

Ms. Houston supports the development of healthcare services locally by serving as a member of the Expert Council on the American Chamber of Commerce in Shanghai’s Healthcare Committee and as the Committee’s liaison with healthcare services members; and as a Board member of the China Healthcare Executive Group (CHEG), an organization that provides continuous professional development opportunities to healthcare leaders across Shanghai in affiliation with the American College of Healthcare Executives (ACHE).

Ms. Houston is a native English speaker who is fluent in Mandarin Chinese. She holds a Master’s degree in Public Health from the Department of Health Policy & Management at the University of North Carolina - Chapel Hill's Gillings School of Global Public Health, and graduated cum laude from Vermont's Middlebury College with a Bachelor of Arts degree in Political Science and Chinese. She was recently appointed to the newly-established Middlebury College Asia Council, an advisory body designed to further Middlebury’s initiatives and priorities in Asia and to participate and provide input into the College’s strategic planning process with regard to Asia-related initiatives.